BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Torrent Pharmaceuticals Ltd.’s Ebitda and profit after tax were above estimates while revenue was inline.
Revenue stood at Rs 25.9 billion (largely inline), grew by 10.4%/4.0% YoY/QoQ. Ebitda stood at Rs 7.9 billion (above estimate), grew by 11.1%/8.8% YoY/QoQ.
Torrent Pharma's Ebitda margin at 30.5% (+19 bps/+134 bps YoY/QoQ) was slightly higher than our estimate of 29.5% mainly on higher gross margins. Profit after tax at Rs 3.8 billion (above estimate) grew by 6.8%/31.7% YoY/QoQ on higher other income and lower tax.
We upgrade our earnings estimates by 13.6%/11.8% in FY24E/FY25E assuming higher Ebitda margin, other income and lower tax rate versus earlier.
We maintain 'Accumulate' rating with a revised target price of Rs 2,376.
Click on the attachment to read the full report:
Also Read: Torrent Pharma Q1 Results Review - Steady Outperformance In Branded Generics Market: Motilal Oswal
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Ambuja Cement, JK Cement Are Dolat Capital's Top Picks In Cement Space; Q2 Results Review
Torrent Pharma, Apollo Hospitals, Hitachi, Somany, Lupin, J Kumar, MCX, Aster, Amber & More Q2 Review
LIC, Mankind Pharma, Aurobindo Pharma, Godrej Properties, Birlasoft, Metropolis, Symphony & More Q2 Review
Jefferies Keeps Mankind Pharma Among Top Picks Despite Q2 Setback — Check Revised Target Price
POPULAR